Fig. 3

Annualised moderate-to-severe exacerbation rate: a In the overall population (pre-specified analysis) and in the subgroup of patients with a chronic bronchitis phenotype (post-hoc analysis); b By eosinophil count at baseline (post-hoc analysis); and c In the subgroup with a chronic bronchitis phenotype by eosinophil count at baseline (post-hoc analysis). d Adjusted rate ratio versus placebo, overall, in the subgroup of patients with a chronic bronchitis phenotype, and in the subgroup of patients with a chronic bronchitis phenotype who also had eosinophil count ≥150 cells/μL at baseline. (All in the ITT population.). Data in Panels a, b and c are adjusted mean and 95% confidence intervals; data in Panel d are rate ratios and 95% confidence intervals. *p < 0.05 vs placebo; ^†p < 0.05 vs budesonide. ITT, intention-to-treat; BID, twice daily